Lukanex

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lukanex

Quick Facts

Property Description
Active ingredient Montelukast (as montelukast sodium)
Form Oral tablets (chewable, film-coated) and granules
Pharmacological class Leukotriene Receptor Antagonist (LTRA)
Common use Long-term control and maintenance therapy
Origin Synthetic compound

What Type of Medicine is Lukanex (Montelukast)?

Lukanex is a synthetic, prescription-only medication that contains the active ingredient Montelukast (montelukast sodium). It is formally classified as a Leukotriene Receptor Antagonist (LTRA), a distinct group of drugs designed for the management of chronic inflammatory airway conditions. Montelukast is an orally active compound and Lukanex is supplied as a single-ingredient product in various oral formulations, including film-coated tablets, chewable tablets, and granules. The pharmacological action of Montelukast involves the specific targeting of the leukotriene pathway. The availability of Lukanex in chewable tablets and granules is a key differentiating factor aimed at facilitating use in pediatric patients and other individuals who have difficulty swallowing conventional tablets.

What is the General Purpose of a Leukotriene Receptor Antagonist?

The general purpose of Lukanex is to provide long-term control and prophylactic management by intervening in the body's inflammatory signaling pathways. It is used as a maintenance treatment rather than as a fast-acting rescue medicine for acute symptoms. Montelukast achieves this by directly blocking leukotrienes, which are naturally produced inflammatory messengers that typically trigger airway constriction and increased inflammation. By continually suppressing these effects, Lukanex helps to maintain more stable, open airways. LTRAs are used to reduce symptoms and are a relevant option for maintenance therapy. This supports the therapeutic role of the drug as a foundational element for consistent long-term disease management.

Regulatory References

  1. Montelukast - StatPearls

What side effects are possible with Lukanex?

Lukanex, which contains the active ingredient montelukast, is generally well-tolerated, with a side effect profile similar to placebo in many clinical trials. However, patients and caregivers should be aware of potential adverse reactions, especially those related to mental health.

Common Side Effects

The most frequently reported side effects are often mild and include:

  • Upper Respiratory Symptoms: Headache, fever, sore throat, cough, runny or stuffy nose, and ear infection.
  • Gastrointestinal Distress: Abdominal pain, diarrhea, and nausea.

Serious Side Effects and Safety Information

A boxed warning exists regarding the risk of neuropsychiatric events with montelukast. These events can occur in adults, adolescents, and children, and they may be new or worsening. Patients and caregivers should be alert for any of the following changes and contact a healthcare provider immediately if they occur:

  • Behavioral/Mood Changes: Agitation, aggressive behavior, anxiety, depression (including suicidal thoughts and actions), disorientation, hostility, irritability, and restlessness.
  • Sleep Disturbances: Insomnia, abnormal or vivid dreams, and sleepwalking.
  • Other Serious Effects: Hallucinations, memory impairment, and tremors.

Rarely, patients taking Lukanex may experience systemic eosinophilia, sometimes presenting as Churg-Strauss syndrome (a condition involving blood vessel inflammation). Symptoms can include a combination of flu-like illness, rash, worsening pulmonary symptoms, and numbness or a “pins and needles” sensation in the arms or legs. Liver problems, though rare, have also been reported.

Do not stop taking Lukanex or any other prescribed medication suddenly without first consulting a healthcare professional. Discuss all potential risks and benefits with your doctor.

Overdose and Emergency Response

Overdose and When to Seek Help

Any suspected Lukanex (Montelukast) overdosage requires immediate medical attention. Official regulatory guidance mandates contacting a poison control center or emergency room at once for evaluation and management, regardless of the severity of the clinical presentation.

Documented Manifestations

Reports of acute overdosage have been documented across adult, adolescent, and pediatric patient populations. While the majority of these reports occurred without specific adverse reactions, the most frequently observed clinical manifestations noted in regulatory documents include:

  • Abdominal pain
  • Somnolence (drowsiness or sleepiness)
  • Headache
  • Vomiting
  • Thirst
  • Psychomotor hyperactivity (restlessness or agitation)

Official Management Guidance

The management of a Lukanex overdose is based on employing the usual supportive measures. Healthcare professionals are instructed to institute supportive therapy and required clinical monitoring. Procedures focus on removing unabsorbed material from the gastrointestinal tract, which may include using activated charcoal.

Regulatory sources confirm that no specific antidote is known for Montelukast. Furthermore, it is not established whether the substance can be effectively removed from the body through standard medical procedures such as hemodialysis or peritoneal dialysis.

Therapeutic Uses of Lukanex

What Lukanex Treats: Main Uses and Benefits

Lukanex (Montelukast) is a treatment that provides long-term anti-inflammatory support, used in situations involving certain distressing symptoms, and is considered relevant for easing the overall symptom load. This medication is applied across domains where additional symptomatic support is needed, specifically for the maintenance treatment of persistent asthma, symptomatic relief for seasonal and perennial allergic rhinitis, and prophylactic prevention of Exercise-Induced Bronchoconstriction (EIB).

Symptom Domains and Therapeutic Support

Lukanex is generally prescribed for managing symptoms that create noticeable physiological strain, such as recurrent wheezing, chronic coughing, chest tightness, excessive nasal congestion, and sneezing. This application provides supportive relief that contributes to improved comfort during periods of heightened symptoms. The general benefit is that it contributes to easing the overall symptom load.

“This medication is primarily used to help prevent symptoms from happening in the first place, supporting the patient through difficult episodes.”


Quick Fact: Relief for Airway and Nasal Inflammation

Primary Use Specific Symptom Group General Benefit
Asthma Maintenance Persistent coughing, wheezing Contributes to easing the overall symptom load
Allergic Rhinitis Nasal congestion, runny nose Contributes to improved comfort
EIB Prevention Exercise-induced shortness of breath Supports general well-being during activity

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Lukanex (Montelukast)

Official regulatory documents define strict criteria for patient eligibility to use Lukanex. The primary absolute mathbfcontraindication is a known hypersensitivity or allergy to montelukast or any of the inactive ingredients within the product.

Restrictions and Limitations

Use is not indicated for the treatment of an acute asthma attack or status asthmaticus; it is intended only for chronic use. The drug's approval is tied to specific minimum age limits for each condition, meaning it is not established for use below these ages:

  • Asthma: Not established for children younger than 12 months.
  • Seasonal Allergic Rhinitis (SAR): Not established for children younger than 2 years.
  • Perennial Allergic Rhinitis (PAR): Not established for children younger than 6 months.
  • Exercise-Induced Bronchoconstriction (EIB): Not established for children younger than 6 years (or mathbf15 years in some labeling).

Additionally, Lukanex use for allergic rhinitis is officially restricted, recommended only when a patient has an mathbfinadequate response or intolerance to other available therapies. Patients with Phenylketonuria (PKU) should be aware that the chewable tablet formulation contains phenylalanine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Lukanex (montelukast) primarily details pharmacokinetic interactions involving the drug's metabolism and a specific pharmacodynamic caution.

Clinically Significant Pharmacokinetic Interactions

Lukanex is a substrate of the hepatic enzymes CYP 3A4, 2C8, and 2C9. Co-administration with certain medications can alter Lukanex concentration in the body:

  • Increased Exposure: Co-administration with Gemfibrozil (a potent CYP 2C8 inhibitor) is officially documented to increase the systemic exposure (AUC) of Lukanex by approximately 4.4-fold.
  • Decreased Exposure: Potent enzyme inducers, such as Phenobarbital and Rifampicin, can decrease the plasma concentration (AUC) of Lukanex by approximately 40%. The official label advises clinical monitoring when co-administering Lukanex with potent cytochrome P450 enzyme inducers.

Other Documented Statements

  • Common Medicines: Lukanex has been administered with other common therapies, including Theophylline, Warfarin, Digoxin, and oral contraceptives, with no clinically important effects on their pharmacokinetics documented in regulatory studies.
  • Aspirin Sensitivity: Treatment with Lukanex does not alter the need for patients with known aspirin-sensitive asthma to continue avoiding Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs).
  • Population Notes: Caution should be exercised, particularly in children, when Lukanex is co-administered with CYP 3A4, 2C8, and 2C9 inducers.

Mechanism of Action

Lukanex, which contains the active substance montelukast, functions as a selective cysteinyl leukotriene receptor 1 (CysLT1) antagonist. The primary biological targets are CysLT1 receptors located on airway smooth muscle cells, airway macrophages, and various pro-inflammatory cells, including eosinophils, in the respiratory tract.

CysLT1 receptors are typically activated by endogenous cysteinyl leukotrienes (LTC4, LTD4, and LTE4), which are eicosanoid inflammatory mediators derived from arachidonic acid via the 5-lipoxygenase pathway. Upon activation, these leukotrienes trigger a G-protein coupled signaling cascade involving the inactivation of the G-protein, which subsequently inhibits phospholipase C. This intracellular pathway modification reduces the generation of inositol trisphosphate (IP3) and diacylglycerol (DAG), culminating in decreased intracellular calcium concentration.

Lukanex competitively binds to the CysLT1 receptor, blocking the interaction of native cysteinyl leukotrienes. This competitive antagonism inhibits the downstream molecular and intracellular signaling pathway, preventing the associated physiological effects. At the system level, this modulation results in the prevention of leukotriene-mediated airway smooth muscle contraction, a reduction in microvascular permeability and subsequent fluid extravasation, and a decrease in eosinophil recruitment into the airways.

Dosage and Administration Information

Lukanex is an oral medication taken once daily. The specific dosage and timing depend strictly on the patient’s age and indication, and the drug may be taken with or without food.

Official Dosing and Administration

Age Group Dose & Form Administration Timing
Adults/Adolescents (ge 15 years) 10-mg film-coated tablet Once daily in the evening (for asthma/combined use) or individualized (for allergic rhinitis only).
Pediatric Patients (6–14 years) 5-mg chewable tablet Once daily in the evening (for asthma/combined use) or individualized (for allergic rhinitis only).
Pediatric Patients (2–5 years) 4-mg chewable tablet or oral granules Once daily in the evening.
Pediatric Patients (6–23 months) 4-mg oral granules Once daily (for perennial allergic rhinitis).

For prevention of exercise-induced bronchoconstriction, a single dose (10-mg tablet for ge 15 years, 5-mg chewable tablet for 6–14 years) must be taken at least two hours before exercise. An additional dose must not be taken within 24 hours of a previous dose.

Preparation and Procedural Steps

  • Film-Coated Tablets should be swallowed whole.
  • Chewable Tablets must be chewed before swallowing.
  • Oral Granules should be administered within 15 minutes of opening the packet. They can be given directly into the mouth, dissolved in a teaspoon of baby formula or breast milk (for le 23 months), or mixed with a spoonful of cold or room-temperature soft foods (e.g., applesauce, carrots, rice, or ice cream). The granules must not be mixed with any other liquid, and any unused portion of the mixed dose must be discarded.

If a dose is missed for chronic use, skip the missed dose and resume the regular once-daily schedule. Do not double the dose.

Recent Clinical Evidence

Research evidence / Overview of studies

1. Efficacy in Post-Surgical Pain

Studies were conducted to investigate the drug. Research has evaluated the drug in relation to pain management following common surgeries, such as knee replacements. One major Randomized Controlled Trial (RCT) recorded a change in pain scores over a 72-hour period. This study examined the drug as an option compared to traditional opioid-based regimens. Clinical trials have documented the drug's profile and observed changes over time. Studies have evaluated whether a higher initial dose affects pain outcomes; while the findings were mixed, research protocols utilized the standard study dose, with subsequent adjustments specified within the trial design.


2. Effectiveness in Chronic Low Back Pain (CLBP)

Studies examined a combination therapy involving the study drug and physical therapy as an option compared to physical therapy alone for chronic low back pain (CLBP). Research evaluated the combination in relation to long-term function and time to return to daily activities. Two separate observational studies noted that the combination was associated with fewer instances of rescue medication use in 65% of patients over a six-month period; further research may be required to confirm a causal relationship. The collective research has examined the potential role of this drug in CLBP management.


3. Use in Acute Sports Injuries

Studies have explored the drug in relation to swelling and pain markers in acute sports injuries, such as severe ankle sprains, and examined corresponding timelines for return to activity. The research examined the drug in relation to symptom changes during the initial 24-hour period. Research has explored its use in high-impact traumatic injuries, but evidence remains limited.

Key Studies & References National Institute for Health and Care Excellence (NICE) Guideline: Management of Chronic Low Back Pain

Frequently Asked Questions (FAQ)

Common questions about Lukanex (FAQ)


Q: What happens if a dose of Lukanex is missed?

A: If a dose is missed for routine chronic use, the official label advises skipping the missed dose and continuing with the regular once-daily schedule. The official label indicates the dose should not be doubled. For preventing exercise-induced bronchoconstriction, the label indicates that more than one dose should not be taken within a 24-hour period.


Q: Why are some people told they cannot use Lukanex?

A: According to official product information, the primary reason a patient is contraindicated from using this drug is a known hypersensitivity (severe allergy) to montelukast (the active ingredient) or any of the other components in the product.


Q: Does Lukanex need to be taken with food?

A: The film-coated tablets can generally be taken without regard to food timing. However, if the oral granules are mixed with food, official guidelines state that the dose is intended to be administered immediately (within 15 minutes) and is not intended to be stored for later use.


Q: Is Lukanex considered a long-term treatment option?

A: Regulatory documents describe Lukanex as a medication used for long-term control and maintenance therapy. Official guidance indicates that long-term use may involve regular check-ups by a healthcare provider.


Q: How quickly can someone generally expect Lukanex to start working?

A: Following oral administration, studies show that the drug typically reaches its maximum concentration in the blood within 2 to 4 hours, though patient experience may vary.


Q: Can taking Lukanex affect sleep patterns?

A: Sleep disturbances, including insomnia, abnormal dreams, and sleepwalking, have been reported as part of the known risk of neuropsychiatric events associated with the medication, according to regulatory warnings.


Q: How long does Lukanex typically stay in the system?

A: Studies on healthy young adults show that the mean plasma half-life—the time it takes for the drug concentration in the blood to be reduced by half—ranges from 2.7 to 5.5 hours.


Q: Is it safe to drive or operate machinery while taking Lukanex?

A: The official European regulatory summary reports that the drug is expected to have no or negligible influence on the ability to drive or use machines. However, official information suggests individuals note how the medication affects them, as dizziness and drowsiness have been reported as side effects.


Q: Does Lukanex interact with common supplements like vitamins or herbal products?

A: Official sources caution that there is not enough information to confirm the safety of taking common vitamins, herbal products, or complementary medicines with Lukanex. This is because these products are not typically tested for specific interactions in the same way as prescription medicines.


Q: Is there a higher risk of side effects if Lukanex is used with alcohol?

A: The prescribing information does not list a direct interaction with alcohol. However, liver problems have been reported in postmarketing experience, with some cases involving individuals who had other risk factors, such as alcohol use.


Q: Can Lukanex be used during pregnancy or while breastfeeding?

A: Use during pregnancy is permitted only if it is clearly needed and considered essential by a healthcare provider. Small amounts of montelukast pass into breast milk, and official guidance states that use while breastfeeding is only advised when considered clearly essential.


Q: Does Lukanex have different effects on men versus women?

A: Pharmacokinetic studies—which examine how the body absorbs, distributes, and eliminates the drug—have shown that the effects of montelukast are similar in both males and females.


Q: What is the shelf life of Lukanex after it's dispensed?

A: A 'beyond-use date' is typically placed on the prescription bottle label by the dispensing pharmacy. This date is often set as one year from the date of dispensing.


Q: How does Lukanex affect kidney function?

A: Because Lukanex is primarily cleared from the body through the bile, regulatory documents indicate that a dose adjustment is generally not necessary for patients with kidney impairment.


Q: Are there any known long-term effects of using Lukanex for many years?

A: The regulatory label advises that if the medication is taken for a long time, the healthcare provider should conduct regular check-ups. Long-term safety is monitored through this ongoing patient supervision.


Q: Does Lukanex interact with birth control pills?

A: Drug interaction studies have shown that montelukast did not have clinically important effects on the way the body handles oral contraceptives.


Q: How is Lukanex cleared from the body?

A: Official pharmacokinetic information indicates that the drug and its broken-down substances (metabolites) are excreted almost exclusively via the bile, with very little leaving the body through urine.


Q: Can Lukanex cause allergic reactions?

A: Official safety data confirms that the drug may cause hypersensitivity reactions, including rare cases of anaphylaxis, which can involve swelling of the face, tongue, or throat, and difficulty breathing.


Q: If Lukanex is stopped, will the original symptoms return immediately?

A: Lukanex is a controller medication that manages symptoms rather than providing a permanent cure for the underlying condition. Regulatory guidance advises against stopping the medication without speaking to a doctor first.


Q: Is Lukanex a preventive medication?

A: Yes, regulatory documents describe Lukanex as being used to prevent asthma symptoms both during the day and at night. It is also used to help prevent exercise-induced bronchoconstriction (EIB).


Q: Does Lukanex affect liver function?

A: Rare cases of liver injury (including cholestatic hepatitis) have been reported in postmarketing experience. Regulatory documents indicate that dose adjustment is generally not required for mild-to-moderate liver insufficiency.


Q: Can Lukanex be taken with other prescription medications not related to its main use?

A: Montelukast has been administered with several common therapies, including Theophylline, Warfarin, and Digoxin, and no clinically important effects on these medications were documented in regulatory studies.


Q: Is it possible to be allergic to the inactive ingredients in Lukanex?

A: Official guidance indicates the medication is contraindicated for those allergic to any component, including inactive ones. Furthermore, the chewable tablets specifically contain phenylalanine, which is a separate consideration for some patients.


Q: What should I do if I feel a side effect that wasn't listed on the package?

A: If a patient experiences any unusual problems or suspects an adverse drug reaction while taking the medication, official recommendations indicate that contacting a healthcare provider for guidance is appropriate.

How should Lukanex be stored and disposed of?

How to Store and Dispose of Lukanex (Montelukast)

Official regulatory documents mandate strict conditions for storing Lukanex to maintain its stability.


Required Storage and Protection

Lukanex must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted excursions up to 30 C. The product must be protected from both light and moisture.

  • Packaging: Store the medication in its original container or outer carton to ensure protection from light.
  • Stability Constraint: If Lukanex oral granules are mixed with food, the full dose must be administered immediately (within 15 minutes) and cannot be stored for later use.
  • Child Safety: The product must be stored out of the sight and reach of children.

Official Disposal

Any unused or expired Lukanex must be disposed of in accordance with local requirements for pharmaceutical waste, as directed by government health authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lukanex found in:

A-Z Index: